The pharmaceutical industry is one of the most complex sectors to steer, operating at the intersection of scientific innovation, strict regulation, global supply chains, and growing financial pressure. Leaders must make strategic decisions in an environment shaped by uncertainty, long development cycles, and high expectations around patient safety and access. As a result, steering activities in pharma requires balancing innovation, risk management, and operational resilience.
Drug development is inherently unpredictable, with long timelines, high costs, and frequent clinical failures that make pipeline planning and budget allocation particularly difficult. At the same time, pharmaceutical companies operate under intense regulatory oversight from agencies such as FDA, EMA, and WHO, whose evolving standards impose a significant compliance burden. These factors force organizations to constantly reprioritize programs while managing the risks of delays or costly setbacks.
Pharma supply chains are global and highly sensitive to disruption, from active ingredient shortages to geopolitical tensions affecting key manufacturing regions. Ensuring consistent supply often requires large inventory buffers and continuous risk mitigation strategies. In parallel, maintaining quality and compliance with stringent manufacturing standards adds another layer of complexity, as biologics production, data integrity requirements, and aging facilities increase operational risk and slow decision-making.
The industry faces significant shortages of skilled professionals in areas such as bioprocessing, regulatory affairs, data science, and automation. This talent gap makes it harder to scale operations or drive transformation programs. Additionally, many organizations still rely on fragmented legacy systems that limit real-time visibility and hinder the adoption of advanced analytics or AI-driven decision-making, resulting in slower and more reactive governance.
Rising costs across R&D, clinical operations, manufacturing, and compliance coincide with increasing pressure on drug pricing and reimbursement. Even after approval, market access remains uncertain due to country-specific regulations and competition from generics and biosimilars. Combined with evolving patient expectations and geopolitical instability, these pressures require pharmaceutical leaders to constantly reassess priorities and build resilient, globally coordinated strategies.
Qu’il s’agisse de cartographier les risques, de mesurer la performance des activités ou de rester en conformité, nos cockpits vous offrent une vue 360° de la santé de votre activité, dans une interface simple et intuitive, vous permettant ainsi de vous assurer de votre résilience opérationnelle.
